论文部分内容阅读
目的检测乳腺浸润性导管癌中CD44v6分子的表达,探讨其与乳腺浸润性导管癌各临床病理特征的相关性、对预测乳腺浸润性导管癌患者预后的意义以及新辅助化疗对CD44v6分子的影响。方法用免疫组化染色法检测90例乳腺浸润性导管癌化疗前后及10例癌旁非肿瘤乳腺组织中CD44v6的表达,并对所有乳腺浸润性导管癌患者进行随访。结果乳腺浸润性导管癌组织中,CD44v6阳性表达率为81.1%(73/90),明显高于癌旁非肿瘤乳腺组织(0/10);CD44v6的表达与组织学分级、肿瘤大小、腋窝淋巴结转移及转移个数呈正相关,而与患者的年龄、月经状况、ER、PR、CerBb-2、P53之间无显著相关性;CD44v6阴性组的总体生存率明显高于CD44v6阳性组,且CD44v6阳性表达越强,患者总生存率越低;Cox比例风险模型多因素分析显示,CD44v6为影响预后的独立因素;介入化疗组和静脉化疗组化疗前后CD44v6的表达差异均无统计学意义。结论CD44v6分子在乳腺浸润性导管癌的诊断中具有较强的特异性;CD44v6分子可作为预测乳腺浸润性导管癌预后的指标之一,但不能作为判断新辅助化疗疗效的指标。
Objective To detect the expression of CD44v6 in invasive ductal carcinoma of the breast and to explore the relationship between the expression of CD44v6 and clinicopathological features in invasive ductal carcinoma of the breast and its significance in predicting the prognosis of patients with invasive ductal carcinoma of breast and the effect of neoadjuvant chemotherapy on CD44v6. Methods The expression of CD44v6 in 90 cases of breast invasive ductal carcinoma before and after chemotherapy and in 10 cases of adjacent non-cancerous breast tissues were detected by immunohistochemical staining. All breast invasive ductal carcinomas were followed up. Results The positive rate of CD44v6 in breast invasive ductal carcinoma was 81.1% (73/90), which was significantly higher than that in adjacent non-cancerous breast tissues (0/10). The expression of CD44v6 was correlated with histological grade, tumor size, axillary lymph nodes There was a positive correlation between the number of metastasis and metastasis and the age, menstrual status, ER, PR, CerBb-2 and P53. The overall survival rate of CD44v6 negative group was significantly higher than that of CD44v6 positive group, and CD44v6 positive The higher the expression was, the lower the overall survival rate was. Cox proportional hazards model multivariate analysis showed that CD44v6 was an independent prognostic factor. There was no significant difference in the expression of CD44v6 before and after interventional chemotherapy and intravenous chemotherapy. Conclusions CD44v6 is highly specific in the diagnosis of invasive ductal carcinoma of the breast. CD44v6 can be used as an index to predict the prognosis of invasive ductal carcinoma of the breast, but it can not be used as an index to evaluate the efficacy of neoadjuvant chemotherapy.